Fate Therapeutics develops off-the-shelf cell immunotherapies made from stem cells, mainly for autoimmune diseases and cancer. It last closed at $0.92 on Nov 20, down 9.01% on the day. The next earnings report for FATE is expected around Thu, Feb 25, 2027. For the quarter ended Sep 2026, FATE reported EPS of -$0.25 on revenue of $0, with revenue down 100.0% from a year ago. Over its last 8 reports the stock moved an average of 9.2% the session after earnings. Over the last 12 months FATE insiders bought $0 of stock on the open market and sold $336K, according to SEC Form 4 filings.
AI Auto Pilots
Is FATE in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold FATE.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on FATEStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
FATE · as of the Nov 20 close · updated each morning
Downtrend, oversold
The stock is 82% below its 20 day and 119% below its 50 day average. It is 116% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 19), oversold. The nearest support is the 52 week low at $0.90, and the nearest resistance the Pivot at $0.95.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 16.1%/day
Key levels
$3.2352 week high+251.1%
$2.32100 day average+152.2%
$2.15Swing high (Oct 20)+133.7%
$2.0150 day average+118.5%
$1.98200 day average+115.2%
$1.6720 day average+81.5%
$1.00Pivot R1+8.7%
$0.95Pivot+3.3%
$0.92Last close
$0.9052 week low−2.2%
$0.87Pivot S1−5.4%
Indicators
RSI (14)
18.97
Oversold below 30
Oversold
MACD
-0.31
Below its signal line
Bearish
Stochastic
1.7
Near the bottom of its range
Oversold
ADX (14)
33.5
Trending down
Williams %R
-98.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-125.7
Oversold below −100, overbought above 100
Oversold
Rate of change
−49.9%
Change over 10 sessions
Bearish
ATR (14)
$0.15
Typical daily range, 16.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 44.9%/day
Key levels
$3.2352 week high+251.1%
$2.32100 day average+152.2%
$2.15Swing high (Oct 20)+133.7%
$2.0150 day average+118.5%
$1.98200 day average+115.2%
$1.6720 day average+81.5%
$1.00Pivot R1+8.7%
$0.95Pivot+3.3%
$0.92Last close
$0.9052 week low−2.2%
$0.87Pivot S1−5.4%
Indicators
RSI (14)
33.41
Weak, oversold below 30
Neutral
MACD
-0.14
Below its signal line
Bearish
Stochastic
4.3
Near the bottom of its range
Oversold
ADX (14)
28.1
Trending down
Williams %R
-99.0
Oversold below −80, overbought above −20
Oversold
CCI (20)
-253.4
Oversold below −100, overbought above 100
Oversold
Rate of change
−60.2%
Change over 10 sessions
Bearish
ATR (14)
$0.41
Typical daily range, 44.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for FATE
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how FATE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow FATE usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for FATEHow many large options trades hit FATE, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in FATE in the last 90 days.
From SEC Form 4 filings by FATE's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether FATE is in one of them and how their past FATE trades turned out.
From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data
About Fate Therapeutics
Fate Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California. It develops off-the-shelf cellular immunotherapies, mainly CAR T-cell and natural killer cell product candidates made from induced pluripotent stem cells. Its current focus is on treating autoimmune diseases such as lupus, along with cancer, and its candidates are being studied in clinical trials for patients with these conditions.